Mercedes
Salgado Fernández
Publicacións (50) Publicacións de Mercedes Salgado Fernández
2024
-
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study
Clinical and Translational Oncology
-
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study
Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer
Genomics, Vol. 114, Núm. 6
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study
Journal of Clinical Medicine, Vol. 11, Núm. 7
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
Venous Thromboembolism In Cancer Patients: “From Evidence to Care”
Clinical and Applied Thrombosis/Hemostasis, Vol. 28
2021
-
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839
-
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
BMC Cancer, Vol. 21, Núm. 1
-
The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study
Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 11, pp. 2791-2800
2020
-
Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: The avamet study
Cancers, Vol. 12, Núm. 8, pp. 1-12
-
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359
-
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
Journal of Geriatric Oncology, Vol. 11, Núm. 8, pp. 1263-1267
-
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
Clinical and Translational Oncology, Vol. 22, Núm. 4, pp. 495-502
-
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
International Journal of Colorectal Disease, Vol. 35, Núm. 4, pp. 739-746
-
Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report
Case Reports in Oncology, Vol. 13, Núm. 1, pp. 69-75
2019
-
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers
Cancer Medicine, Vol. 8, Núm. 3, pp. 882-889